<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Durbin</surname>
    <given-names>A. P.</given-names>
   </name>
   <name>
    <surname>Whitehead</surname>
    <given-names>S. S.</given-names>
   </name>
   <name>
    <surname>McArthur</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Perreault</surname>
    <given-names>J. R.</given-names>
   </name>
   <name>
    <surname>Blaney</surname>
    <given-names>JE</given-names>
    <suffix>Jr.</suffix>
   </name>
   <name>
    <surname>Thumar</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2005</year>). 
  <article-title>rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.</article-title>
  <source>
   <italic>J. Infect. Dis.</italic>
  </source>
  <volume>191</volume>
  <fpage>710</fpage>â€“
  <lpage>718</lpage>. 
  <pub-id pub-id-type="doi">10.1086/427780</pub-id>
  <?supplied-pmid 15688284?>
  <pub-id pub-id-type="pmid">15688284</pub-id>
 </mixed-citation>
</ref>
